Our ability to quantify FUS cytoplasmic mislocalisation following staurosporine treatment also demonstrates the possibility of this technique for use in testing the ability of novel FTD and ALS drug treatments to modulate FUS or TDP-43 mislocalisation. This evidence concerns the gene FUS and amyotrophic lateral sclerosis.